Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP4 | P49662 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477312 | 0.87 | LMNA (0.48) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL1654554 | 0.79 | NOTUM (0.57) | LMNAHSPA9GAAALDH1A1SIRT2 | |
| SCHEMBL13234025 | 0.79 | ALDH1A1 (0.47) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL9593368 | 0.78 | ALDH1A1 (0.51) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL795900 | 0.76 | POLB (0.40) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL2062014 | 0.75 | ALDH1A1 (0.48) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL13234154 | 0.74 | POLB (0.47) | LMNAL3MBTL1GAAALDH1A1TDP1 | |
| SCHEMBL28931189 | 0.73 | MAPT (0.43) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL20335481 | 0.73 | LMNA (0.44) | LMNAHSPA9L3MBTL1CASP6CASP1 | |
| SCHEMBL9917021 | 0.73 | SLC6A2 (0.42) | L3MBTL1ALDH1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105873919-A | Substituted uracils as chymase inhibitors | 拜耳医药股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1678173-A2 | 4-HETEROBICYCLYLAMINO-SUBSTITUTED QUINAZOLINES AND ANALOGUES THEREOF AS CAPSAICIN-ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005023807-A2 | 4 - HETEROBICYCLYAMINO - SUBSTITUTED QUINAZOLINES AND ANALOGUES THEROF AS CAPSAICIN - ANTAGONISTS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1299391-B1 | INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | JOHNSON & JOHNSON VISION CARE (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6803471-B2 | USEFUL AS PHOTOCHROMIC COMPOUNDS; COVALENTLY ATTACHED TO WANG RESINS AND METHOD OF ATTACHING; OPHTHALMIC LENSES | JOHNSON & JOHNSON VISION CARE, INC. | 2004-10-12 | — | — | US | disclosed |
| EP-1299391-A2 | INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | Johnson & Johnson Vision Care, Inc. (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6521753-B1 | Indolinospiropyran compounds and methods for their manufacture | JOHNSON & JOHNSON VISION CARE, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020087010-A1 | Indolinospiropyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2002-07-04 | — | — | US | disclosed |
| WO-2001092265-A2 | INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | LMNA 1870/4885HSPA9 3642/4885L3MBTL1 2321/4885 |
| US-20020087010-A1 | Indolinospiropyran compounds and methods for their manufacture | DHPS, IDO1, INMT | LMNA 2416/4885HSPA9 3079/4885L3MBTL1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.